Over my decades in investing, I’ve learned the hard way that recognizing mistakes as quickly as possible, and then acting decisively to fix them – if need be, by trimming or exiting a position – is one of the cardinal attributes that separate professionals from amateurs. And so you can count on me to raise
Global interest-rate cuts have sent share prices toward all-time highs, along with many of the names in The Big Secret on Wall Street portfolio. Our commodities holdings in particular have benefitted from this rate-cutting environment, with the shares of our coal, oil, and mining related companies posting double-digit returns over the last month.
For a variety of economic reasons, biotech has not participated in the current tech rally. And, as a result, there has likely never been a wider gap between tech stocks and biotech stocks. Right now, as we report in this week’s issue, a major biotech bull market is forming.
This week we report on a one-time railroad company that has become one of the greatest success stories in American finance – finding capital efficient ways to generate new revenue and maintaining 60% profit margins for decades.
Today we’re discussing how rate cuts and consumer weakness play out in the markets, what might happen, and how to prepare. What follows are hard-earned, actionable insights from Porter Stansberry, based on his 25 years of navigating markets.
Shares of America’s largest insurer soared in August after a strong earnings report, Warren Buffett bought into one Big Secret portfolio company, and a beverage company continues to show promise despite months of struggling to increase sales.
With a 64% probability of the Fed cutting interest rates in September, the macro economic environment is clearly shifting in the right direction for biotech, but even before that has happened, these two companies released blowout earnings reports.
The share prices of the four businesses we review in this issue got whacked by the overall slowdown in the economy – but except for one that we recommend selling, the long-term outlook for them remains bullish.
This company went from making addictive products that can kill you, to making addictive products that don’t kill you, and it’s generating huge margins doing so. It has all the ingredients of a high-conviction opportunity, when investors can make money with almost 100% certainty.
The economy has reached a critical inflection point, with widespread consumer distress and a stalling labor market signaling an imminent recession. We’re bracing for a bear market, and providing an update on some of the recommendations in The Big Secret portfolio.